home / stock / nvsef / nvsef news


NVSEF News and Press, Novartis Ag Basel Akt From 03/19/24

Stock Information

Company Name: Novartis Ag Basel Akt
Stock Symbol: NVSEF
Market: OTC
Website: novartis.com

Menu

NVSEF NVSEF Quote NVSEF Short NVSEF News NVSEF Articles NVSEF Message Board
Get NVSEF Alerts

News, Short Squeeze, Breakout and More Instantly...

NVSEF - AstraZeneca-Fusion deal reignites radiopharma space

2024-03-19 08:19:47 ET More on Fusion Pharmaceuticals Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook Biggest stock movers today: FUSN, NCMI, crypto stocks and more AstraZeneca will buy Fusion Pharmaceuticals for ~$2B Seeking Alpha’s ...

NVSEF - Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point

2024-03-12 12:09:42 ET Summary Bicycle Therapeutics plc results from the phase 1/2 Duravelo-1 study, using BT8009 for the treatment of patients with metastatic urothelial carcinoma, expected in the 2nd half of 2024. Data from BT5528 [Bicycle toxin conjugate tech] and BT7480 [Bicyc...

NVSEF - Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

2024-03-11 11:53:40 ET Summary Positive interim results released from phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. Functional and strength data from the phase 1/2 AFFINITY study, using RGX-202 for the treatment of patients...

NVSEF - Merck touts new Keytruda version as patent cliff approaches

2024-03-08 14:02:46 ET More on Merck Merck & Co., Inc. (MRK) TD Cowen 44th Annual Healthcare Conference (Transcript) Merck: A Great Dividend Growth Stock, But Not At This Price Merck: A High-Conviction Investment For Long-Term Growth Gilead, Merck once we...

NVSEF - IDEAYA a new Buy at BTIG on underappreciated pipeline

2024-03-08 12:11:45 ET More on IDEAYA, Immunocore, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Ideaya Biosciences: A Strong Bet In Targeted Oncology Immunocore Holdings: Vulnerable To Profit Taking After Big Rally Immunocore to work w...

NVSEF - BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

2024-03-08 05:10:00 ET Summary BeiGene's revenue surged 73.7% to $2.46 billion last year. But for all the success with its flagship product, the drug maker was not able to power all the way into the black. Undeterred by the continuing losses, investors welcomed the bumper sale...

NVSEF - Sandoz biosimilars targeting Amgen's Prolia, Xgeva cleared

2024-03-05 14:33:12 ET More on Sandoz Biggest stock movers today: Boeing, NuStar Energy, Archer-Daniels-Midland, and more Sandoz to acquire Cimerli business from Coherus BioSciences for $170M in all-cash deal Historical earnings data for Sandoz Group AG Finan...

NVSEF - Radiopharmaceutical market expected to reach ~$14B by 2032

2024-02-25 12:00:00 ET More on AstraZeneca, Bristol-Myers, etc. Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly: Very Strong Fundamentals, But Market Is Euphoric Phase 3 data for As...

NVSEF - Tweedy, Browne Fund Q4 2023 Commentary

2024-02-14 21:40:00 ET Summary Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, ...

NVSEF - Federal judge dismisses PhRMA challenge to Medicare price negotiations

2024-02-12 21:01:27 ET More on Bristol-Myers Squibb Company , Eli Lilly, etc. Pfizer Stock: It's Time To Buy The Dip Pfizer Is A Great Investment Over The Next Decade; Buy Will Eli Lilly and Company Become A Trillion-Dollar Baby? RayzeBio ticks higher af...

Previous 10 Next 10